Trial intelligence / Profile preview

DW1029M and Metformin PK Interaction Study

NCT02212756Phase 1Completed

Sponsor
Dongwha Pharmaceutical Co., Ltd.
Start
Aug 2014
Primary completion
Jan 2015
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, randomised, open-label trial of DW1029M in diabetic nephropathy (DN) (2 arms), sponsored by Dongwha Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 21 and Area Under the Curve at Day 21. Started Aug 2014; status: completed.

02

Drugs

DW1029M
03

Conditions

diabetic nephropathy (DN)

Beyond the preview

Go deeper on NCT02212756.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02212756.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call